Valuation dashboard for Hemab Therapeutics Holdings, Inc. Common Stock (COAG) with P/E N/A, P/B 2.86, EV/EBITDA -35.9 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $43.10 (closing price, November 3, 2026), COAG has negative trailing earnings (P/E not meaningful) and an ROE of -36.64%. Market capitalisation stands at $2.0B.
Balance sheet quality for COAG: debt-to-equity ratio of 0.00, current ratio of 35.85 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.86 |
| EV / EBITDA | -35.9 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, Inc. Common Stock | $2.0B | 2.86 | -36.6% | |
| IRON | Disc Medicine, Inc. | $3.1B | 4.72 | -37.2% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 6.44 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $91.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $56.7B | 42.51 | 6.74 | 16.9% |
Price
| Price | $43.10 (closing price, November 3, 2026) |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -36.64% |
| Return on Invested Capital | -10.91% |
| Return on Assets | -10.01% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: IRON · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of COAG: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks